Medicenna’s MDNA209 extends median survival up to fourfold in mouse models of acute graft-versus-host disease

• Medicenna Therapeutics reported preclinical results showing long-acting MDNA209 improved symptoms and extended survival in two mouse models of acute graft-versus-host disease.
• Results were presented October 23, 2026, at The Promises of Treg and Interleukin-2 Therapies Conference in Paris.
• Human immune-cell studies showed CD122 blockade suppressed overactive immune cells while preserving regulatory T-cell viability.
• The developer is pursuing potential partnerships for MDNA209, an engineered drug candidate targeting autoimmune and inflammatory diseases.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicenna Therapeutics Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610260852PRIMZONEFULLFEED9852961) on October 26, 2026, and is solely responsible for the information contained therein.